Predictive Oncology Raises $343.5M to Kick Off ATH Treasury
Predictive Oncology Inc. (NASDAQ: $POAI) announced on Wednesday that it has closed two private placements totaling approximately $343.5 million to support a newly announced digital asset treasury strategy centered on (CRYPTO: $ATH), the native utility token of the Aethir ecosystem.
The financing consists of two components. The first is a Cash PIPE, in which Predictive Oncology sold roughly 4.4 million shares (or pre-funded warrants) at $11.6265 per share, generating about $50.8 million in gross cash proceeds.
The second is a Crypto PIPE, under which pre-funded warrants tied to approximately 14.9 million shares were issued in exchange for ATH tokens (locked and unlocked) with notional value of $292.7 million, corresponding to roughly $173.3 million in discounted value of ATH contributions.
The warrants from the Crypto PIPE will become exercisable upon shareholder approval, per the company.
Predictive Oncology described the investment as foundational to a “Strategic Compute Reserve” that complements its AI/ML-driven drug discovery operations and serves as a capital base for its computational demands.
In conjunction with the financing, Predictive Oncology said Shawn Matthews, CEO of DNA Holdings and former CEO of Cantor Fitzgerald, will join its board.
Shares of Predictive Oncology shares (NASDAQ: POAI) closed up 1.68 percent at US$14.50.